Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna, BioNTech, and Novavax Stocks Sank Today

By Keith Speights – Aug 19, 2021 at 5:17PM

Key Points

  • CNBC reported that some scientists are criticizing the U.S. government's decision to move ahead with third booster doses of mRNA vaccines.
  • Results from a large U.K. study showed a rapid decline in efficacy against the delta variant for the Pfizer-BioNTech vaccine.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A couple of developments likely factored into the declines for these vaccine stocks.

What happened

Shares of three leading COVID-19 vaccine makers sank on Thursday. As of the market close, BioNTech (BNTX -0.88%) stock was down 8.8%. Shares of Moderna (MRNA -0.23%) and Novavax (NVAX -2.88%) fell 5.8% and 4.2%, respectively.

None of the companies announced any developments. However, there were a couple of stories that were likely related to the vaccine stocks sinking.

CNBC reported that some scientists are criticizing the U.S. government's decision to move forward with third booster doses of messenger RNA (mRNA) vaccines as premature. Also, results from a large U.K. study were published online. Those results showed that the effectiveness against the delta variant for the COVID-19 vaccines developed by Pfizer (PFE 0.74%) and BioNTech and by AstraZeneca falls off quickly.

Line chart trending down with a coronavirus and stock prices in the background.

Image source: Getty Images.

So what

Some investors could fret that the U.S. might reconsider its position on third booster doses if there's too much pushback from the scientific community. That could potentially impact BioNTech and Moderna. A rapid loss of efficacy against the delta variant could also make the Pfizer-BioNTech vaccine less attractive than other COVID-19 vaccines.

However, it seems highly unlikely that the Biden administration will change its mind on booster doses in light of the ongoing surge in COVID-19 cases. The U.K. study actually bolsters the argument that booster doses could be necessary.

Regardless, the U.S. has already agreed to buy enough doses of the Pfizer-BioNTech and Moderna vaccines to provide third booster doses to all fully vaccinated Americans. And Novavax arguably shouldn't be impacted all that much by any of this news. 

Now what

Many of the moves in these stocks on Thursday were likely more noise than anything significant. There are things to watch with each of the three companies, though, that could cause the stocks to move either higher or lower.

For BioNTech and Moderna, the key catalysts on the way are potential new supply deals for 2022 and beyond as well as the possibility of expanded U.S. authorizations for younger children. The main potential catalysts for Novavax are the anticipated authorizations over the next few months of its COVID-19 vaccine in several countries, including the U.S.

Keith Speights owns shares of Pfizer. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax Stock Quote
Novavax
NVAX
$16.54 (-2.88%) $0.49
Pfizer Stock Quote
Pfizer
PFE
$49.21 (0.74%) $0.36
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.17 (0.08%) $0.05
Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$176.40 (-0.23%) $0.41
BioNTech SE Stock Quote
BioNTech SE
BNTX
$154.85 (-0.88%) $-1.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.